{"product_id":"roche-bcg-matrix","title":"Roche  Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Visual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRoche's BCG Matrix snapshot maps key business units and product lines by market growth and relative share-identifying potential Stars in oncology, Cash Cows in diagnostics and diabetes solutions, and segments that may need attention. This concise preview outlines strategic priorities and resource implications; the full BCG Matrix provides quadrant-level placements, actionable recommendations, and financial context. Purchase the complete report for a Word analysis and Excel summary to inform capital allocation, portfolio pruning, and targeted growth decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVabysmo (Faricimab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVabysmo (faricimab) is Roche's high-growth ophthalmology star, with 2025 sales of CHF 4.1 billion and year-over-year growth above 40%, driven by uptake in wet AMD and DME.\u003c\/p\u003e\n\u003cp\u003eIts flexible dosing (up to every 16 weeks) helped capture market share from Bayer\/Regeneron's Eylea, lowering treatment burden and boosting payer adoption in the US and EU.\u003c\/p\u003e\n\u003cp\u003eRoche is investing in global rollout, real-world evidence programs and head-to-head studies; capex and H2 2025 field spend rose ~25% to secure long-term market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhesgo (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhesgo (breast cancer) is a Roche HER2 franchise star: a fixed-dose subcutaneous combo of pertuzumab and trastuzumab whose sales jumped \u0026gt;50% in 2025, reaching an estimated $1.2bn-$1.4bn globally, driven by faster clinic throughput and higher patient uptake.\u003c\/p\u003e\n\u003cp\u003eIts convenience is rapidly taking share and blunting biosimilar threat, but Roche must fund geographic rollouts and convert IV patients; sustained investment will let Phesgo transition into a cash cow as market penetration exceeds 40% in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcrevus (Multiple Sclerosis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcrevus remains Roche's top-selling drug, posting CHF 7.0 billion in 2025 and holding a leading MS market share (~25% global by revenue).\u003c\/p\u003e\n\u003cp\u003eThe 2024 subcutaneous Zunovo launch broadened uptake-12% of 2025 Ocrevus prescriptions in Europe-and refreshed the brand, extending its lifecycle. \u003c\/p\u003e\n\u003cp\u003eDespite product maturity, robust demand for novel MS therapies keeps Ocrevus in the BCG Stars quadrant: high market share and continued market growth ahead of patent expiries. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemlibra (Hemophilia A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHemlibra (emicizumab) transformed hemophilia A care, delivering double-digit growth to CHF 4.5 billion sales by end-2025 and ranking as a Star in Roche's BCG matrix due to high market share in prophylaxis.\u003c\/p\u003e\n\u003cp\u003eRoche holds dominant prophylaxis share, expanding into pediatric and inhibitor patients globally while investing in next-gen follow-ons to defend vs gene therapies and new competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 4.5 billion sales (2025)\u003c\/li\u003e\n\u003cli\u003eDouble-digit CAGR since 2022\u003c\/li\u003e\n\u003cli\u003eLeading global prophylaxis market share\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D on next-gen follow-ons vs gene therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing (NGS) Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche Diagnostics is shifting to advanced sequencing with SBX, which Roche announced in November 2025 can decode a human genome in under four hours, targeting a personalized medicine market growing at ~14% CAGR to $45B by 2027.\u003c\/p\u003e\n\u003cp\u003eThe unit is first-to-market in clinical genomics, receiving \u0026gt;€1.2bn capex since 2024 to integrate diagnostics with Roche Pharma to drive companion diagnostics and targeted therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSBX: \u0026lt;4-hour genome (Nov 2025)\u003c\/li\u003e\n\u003cli\u003eMarket: ~14% CAGR, ~$45B by 2027\u003c\/li\u003e\n\u003cli\u003eInvestment: \u0026gt;€1.2bn capex since 2024\u003c\/li\u003e\n\u003cli\u003eStrategic goal: tie diagnostics to pharma for higher-margin care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche blockbuster surge: Vabysmo, Ocrevus, Hemlibra, Phesgo drive strong 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche Stars: Vabysmo CHF4.1bn (2025, +40% YoY); Phesgo $1.3bn (2025, +50%); Ocrevus CHF7.0bn (2025, ~25% MS share); Hemlibra CHF4.5bn (2025, double-digit CAGR); Diagnostics SBX \u0026lt;4h genome (Nov 2025), \u0026gt;€1.2bn capex since 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\u003c\/th\u003e\n\u003cth\u003eGrowth\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVabysmo\u003c\/td\u003e\n\u003ctd\u003eCHF4.1bn\u003c\/td\u003e\n\u003ctd\u003e+40% YoY; q16w dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhesgo\u003c\/td\u003e\n\u003ctd\u003e$1.3bn\u003c\/td\u003e\n\u003ctd\u003e+50%; subQ HER2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003eCHF7.0bn\u003c\/td\u003e\n\u003ctd\u003e~25% MS rev share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemlibra\u003c\/td\u003e\n\u003ctd\u003eCHF4.5bn\u003c\/td\u003e\n\u003ctd\u003edouble‑digit CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Roche's portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Roche BCG Matrix mapping units into quadrants for fast strategic decisions and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics Division Core Lab Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche's Diagnostics division, led by centralized lab and pathology platforms, generated about CHF 13.8 billion in 2025, acting as a major cash cow for the group.\u003c\/p\u003e\n\u003cp\u003eThese mature, high-margin platforms hold dominant global shares in core lab and pathology, delivering predictable recurring revenue from consumables and service contracts.\u003c\/p\u003e\n\u003cp\u003eLow growth but strong margins let Roche fund R\u0026amp;D (CHF 13.7 billion group R\u0026amp;D spend in 2024) and sustain dividends while driving efficiency gains to maximize free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlecensa (Lung Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlecensa (alectinib) is Roche's cash cow in ALK+ non‑small cell lung cancer, delivering stable sales around CHF 3.6 billion in 2024 and high operating margins in a mature standard‑of‑care segment.\u003c\/p\u003e\n\u003cp\u003eMarket adoption is entrenched-first‑line global share \u0026gt;60%-so promotional spend is low versus new launches, keeping net cash flow steady.\u003c\/p\u003e\n\u003cp\u003eRoche redirects Alecensa profits to fund its oncology pipeline; Roche invested CHF 11.2 billion in R\u0026amp;D in 2024, much of which supports early‑stage cancer programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXolair (Immunology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXolair (immunology) remains a Roche cash cow, holding top market share in chronic hives and asthma and driving CHF 2.8 billion in sales in 2025 after new food-allergy approvals. The underlying markets are mature, so marginal marketing and R\u0026amp;D costs are low while pricing stays stable. This strong cash flow funds pipeline work and buybacks; Roche expects biosimilar pressure late 2020s, but Xolair will supply reliable liquidity until then.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes Care (Accu-Chek)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Accu-Chek franchise is a cornerstone of Roche's diabetes care, delivering stable cash flow from ~30 million users worldwide and a \u0026gt;40% market share in strip-based SMBG (self-monitoring blood glucose) in 2024, in a mature market with low volume growth.\u003c\/p\u003e\n\u003cp\u003ePricing pressure and single-digit CAGR weigh on revenue, but optimized plants and \u0026gt;25% gross margins keep it a high-margin cash cow funding R\u0026amp;D into digital health and continuous glucose monitoring (CGM).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30M users global\u003c\/li\u003e\n\u003cli\u003e40% strip SMBG market share (2024)\u003c\/li\u003e\n\u003cli\u003eSingle-digit CAGR; pricing pressure\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;25%\u003c\/li\u003e\n\u003cli\u003eFunds CGM\/digital health R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerjeta (Oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePerjeta (oncology) remains a high-volume HER2+ breast cancer drug, generating about CHF 2.1 billion for Roche in 2024 despite patent expiry horizon in the late 2020s; volume growth has slowed as clinicians shift to the Phesgo (subcutaneous pertuzumab\/trastuzumab) combo introduced 2021-2022.\u003c\/p\u003e\n\u003cp\u003eEstablished inclusion in adjuvant and metastatic protocols keeps Perjeta a steady cash source; Roche reported gross margins above 70% on the product in 2024 while prioritizing cost discipline and simplified supply to sustain returns before biosimilar entry intensifies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~CHF 2.1bn\u003c\/li\u003e\n\u003cli\u003eGrowth slowing; Phesgo substitution since 2022\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;70% (2024)\u003c\/li\u003e\n\u003cli\u003ePatent cliff late 2020s; biosimilar risk ahead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's high‑margin cash cows fund CHF13.7bn R\u0026amp;D \u0026amp; dividends amid biosimilar risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's cash cows: Diagnostics platforms CHF 13.8bn (2025); Alecensa CHF 3.6bn (2024); Xolair CHF 2.8bn (2025); Accu‑Chek ~30M users, \u0026gt;40% SMBG share (2024); Perjeta CHF 2.1bn (2024). These mature, high‑margin businesses fund CHF 13.7bn group R\u0026amp;D (2024) and dividends while offsetting late‑2020s biosimilar risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eCHF 13.8bn (2025)\u003c\/td\u003e\n\u003ctd\u003eRecurring consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlecensa\u003c\/td\u003e\n\u003ctd\u003eCHF 3.6bn (2024)\u003c\/td\u003e\n\u003ctd\u003e1st‑line share \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXolair\u003c\/td\u003e\n\u003ctd\u003eCHF 2.8bn (2025)\u003c\/td\u003e\n\u003ctd\u003eTop immunology share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccu‑Chek\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~30M users; \u0026gt;40% SMBG (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerjeta\u003c\/td\u003e\n\u003ctd\u003eCHF 2.1bn (2024)\u003c\/td\u003e\n\u003ctd\u003eGross margin \u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eRoche BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Roche BCG Matrix report you'll receive after purchase-fully formatted, analysis-ready, and free of watermarks or demo content. This document mirrors the downloadable version, crafted with market-backed insights and designed for immediate editing, printing, or presentation. Buy once to unlock the same professional file delivered directly to your inbox-no surprises, no revisions required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Oncology Monoclonal Antibodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHerceptin, Avastin and MabThera\/Rituxan have seen sales drop: combined Roche oncology originator sales fell ~58% from peak to 2024, with Herceptin down ~70% vs peak and MabThera\/Rituxan global sales ~€3.4bn in 2024 amid heavy biosimilar entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder COVID-19 Diagnostic Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of Roche's older COVID-19 diagnostics collapsed from 2020 peaks (roughly CHF 10.0bn group COVID-related testing revenue in 2020-21) to negligible levels by end-2025, falling over 95% as routine testing became low-margin commodity services.\u003c\/p\u003e\n\u003cp\u003eThese assets sit in a low-growth market with low relative share and are classified as Dogs in Roche's BCG matrix; revenue contribution was under 0.5% of Roche Diagnostics sales in 2025.\u003c\/p\u003e\n\u003cp\u003eRoche has reallocated capital and lab capacity toward higher-margin molecular and tissue-based oncology diagnostics-areas that accounted for ~60% of Diagnostics division growth in 2024-25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLucentis (Ophthalmology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLucentis (ranibizumab) has fallen to single-digit global market share by 2025 after biosimilar entry and internal cannibalization by Roche's Vabysmo (faricimab); sales plunged from about CHF 1.5bn in 2019 to under CHF 400m in 2024. It sits in a low-growth legacy anti-VEGF segment and is no longer a strategic priority for Roche. Analysts and Roche filings list Lucentis as a drag on growth, so minimal investment or phased withdrawal is likely. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEsbriet (Respiratory)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEsbriet (pirfenidone) for idiopathic pulmonary fibrosis has seen global sales fall over 60% in key markets since generic entry in 2021-2024; branded market share now under 10% and annual revenue around $150m in 2024, down from ~$600m in 2018.\u003c\/p\u003e\n\u003cp\u003eGrowth for the branded product is negligible against cheaper generics, making Esbriet a cash trap; Roche should reallocate remaining spend to higher-potential respiratory and immunology assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales decline: \u0026gt;60% drop 2018-2024\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ~ $150m\u003c\/li\u003e\n\u003cli\u003eBranded market share: \u0026lt;10% in major markets\u003c\/li\u003e\n\u003cli\u003eRecommendation: divest\/repurpose funds to pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Early-Stage Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025 Roche cut several underperforming early-stage oncology assets, including TIGIT and HER2 bispecific programs that missed clinical milestones; these projects held minimal market share in crowded, uncertain indications and burned cash without returns.\u003c\/p\u003e\n\u003cp\u003eStopping or divesting these Dogs frees portions of Roche's roughly $15 billion annual R\u0026amp;D budget to redeploy toward higher-potential Question Mark candidates with clearer paths to market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025: TIGIT and HER2 bispecifics discontinued\u003c\/li\u003e\n\u003cli\u003eLow market share in competitive oncology niches\u003c\/li\u003e\n\u003cli\u003eHigh burn, no clinical milestones met\u003c\/li\u003e\n\u003cli\u003eReallocation from Dogs supports Roche's $15B R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eFocus shifts to Question Marks with stronger signals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's legacy drugs collapse-\u0026gt;50% revenue drop, tying up CHF15bn R\u0026amp;D capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's Dogs-legacy oncology biologics, older COVID diagnostics, Lucentis, Esbriet and failed early oncology programs-saw combined revenue collapse (\u0026gt;50% decline from peaks), contributed \u0026lt;0.5% of Diagnostics sales in 2025, and tied up reallocable R\u0026amp;D\/capacity from a ~CHF 15bn R\u0026amp;D budget.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003ePeak→2024\/25\u003c\/th\u003e\n\u003cth\u003e2024-25 rev\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerceptin\/Avastin\/MabThera\u003c\/td\u003e\n\u003ctd\u003e-58% combined\u003c\/td\u003e\n\u003ctd\u003e€≈3.4bn (MabThera)\u003c\/td\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID diagnostics\u003c\/td\u003e\n\u003ctd\u003e-95% vs 2020-21\u003c\/td\u003e\n\u003ctd\u003eNegligible by 2025\u003c\/td\u003e\n\u003ctd\u003eCommodity testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLucentis\u003c\/td\u003e\n\u003ctd\u003e-75% vs 2019\u003c\/td\u003e\n\u003ctd\u003e≈CHF 400m\u003c\/td\u003e\n\u003ctd\u003eVabysmo cannibalized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsbriet\u003c\/td\u003e\n\u003ctd\u003e-60% since 2018\u003c\/td\u003e\n\u003ctd\u003e≈$150m\u003c\/td\u003e\n\u003ctd\u003eGeneric erosion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCT-388 (Obesity\/Metabolic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCT-388 is a dual GLP-1\/GIP receptor agonist that entered Phase III in late 2025, marking Roche's high-stakes entry into the obesity\/metabolic market.\u003c\/p\u003e\n\u003cp\u003eRoche currently holds 0% market share in obesity drugs, but analysts project the global anti-obesity market to reach ~USD 110-120 billion by 2030; a successful CT-388 could capture several billion annually.\u003c\/p\u003e\n\u003cp\u003eRoche has committed multi-year, multi-billion CHF investments in manufacturing and development (reported CHF 2-4+ billion range) to scale supply and position CT-388 to become a Star against established players like Novo Nordisk and Eli Lilly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrontinemab (Alzheimer's Disease)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrontinemab, Roche's brain-shuttle anti-amyloid candidate for Alzheimer's, sits in Question Marks: early pivotal trials started by Dec 2025 after promising phase 1\/2 signals (e.g., ~30-40% plaque reduction in exploratory PET subgroups). \u003c\/p\u003e\n\u003cp\u003eNeurodegenerative market set to reach ~$35-40B by 2030; Roche has zero amyloid-clearing share vs leaders Biogen\/Eisai, so uptake is uncertain without clear superiority. \u003c\/p\u003e\n\u003cp\u003eExpect heavy R\u0026amp;D and regulatory spend - likely $1-2B to PDUFA-equivalent approval - and high commercial risk unless phase 3 shows \u0026gt;20-25% clinical benefit on CDR-SB. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGiredestrant (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGiredestrant is a next-generation oral SERD (selective estrogen receptor degrader) for HR-positive breast cancer, targeting a market growing ~7-9% CAGR to ~USD 18-22B by 2028; unmet need remains for endocrine-resistant disease where progression-free-survival gains command premium pricing.\u003c\/p\u003e\n\u003cp\u003eCurrently 0% market share as pivotal Phase III readouts and regulatory filings are expected in 2026; trial enrollment and event-driven timelines will determine launch timing and peak sales potential.\u003c\/p\u003e\n\u003cp\u003eRoche must invest heavily-estimated launch spend USD 300-500M and commercial run-rate ~USD 150-250M\/year early-to differentiate versus fulvestrant, CDK4\/6 inhibitors, and oral SERDs from competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Diabetes Management Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche is shifting into AI-driven digital diabetes care-integrating CGM hardware with analytics and remote monitoring to capture a market expected to reach $16.7B by 2028 (CAGR ~11% from 2023); Roche's current share is single-digit, so this sits as a Question Mark in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on rapid healthcare system adoption and demonstrable outcome gains versus startups; trials must show HbA1c reductions \u0026gt;0.5% and readmission drops to justify reimbursement and scale.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size $16.7B by 2028, CAGR ~11%\u003c\/li\u003e\n\u003cli\u003eRoche market share: low, single-digit percent\u003c\/li\u003e\n\u003cli\u003eKey KPI: HbA1c drop \u0026gt;0.5% for payer uptake\u003c\/li\u003e\n\u003cli\u003eRisk: fragmented competitors and slow system adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T Cell Therapy Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche's CAR-T portfolio sits as Question Marks: after acquiring Poseida Therapeutics in 2023 for about $1.9B, Roche targets allogeneic (off-the-shelf) CAR-Ts for solid tumors and autoimmune disease, a fast-growing area with global CAR-T market projected to reach ~$18B by 2030 but Roche's candidates currently hold low market share and face high technical failure risk.\u003c\/p\u003e\n\u003cp\u003eThe company is increasing R\u0026amp;D spend-Roche's oncology R\u0026amp;D rose to €8.1B in 2024-betting its manufacturing scale and diagnostic unit (Roche Diagnostics, 2024 sales €15.7B) will convert these Question Marks into stars, though timelines to approval remain multi-year and clinical readouts are pivotal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisition: Poseida ~ $1.9B (2023)\u003c\/li\u003e\n\u003cli\u003eMarket outlook: CAR-T market ~ $18B by 2030\u003c\/li\u003e\n\u003cli\u003eRoche oncology R\u0026amp;D: €8.1B (2024)\u003c\/li\u003e\n\u003cli\u003eRoche Diagnostics sales: €15.7B (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: high technical\/clinical failure; low current market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche Bets Big: Zero Share Today, Multibillion Markets Await CT‑388, Trontinemab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's Question Marks: late-stage CT-388 (GLP-1\/GIP) and trontinemab (anti-amyloid) plus giredestrant, AI diabetes tools, and CAR-Ts-large addressable markets (obesity $110-120B by 2030; neuro $35-40B; CAR-T $18B by 2030; diabetes $16.7B by 2028), near-zero Roche share, high R\u0026amp;D\/commercial spend (CHF\/USD 1-4B per asset), outcomes-driven commercial risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eRoche share\u003c\/th\u003e\n\u003cth\u003eSpend est.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCT-388\u003c\/td\u003e\n\u003ctd\u003e$110-120B (2030)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$2-4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrontinemab\u003c\/td\u003e\n\u003ctd\u003e$35-40B (2030)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$1-2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508955279443,"sku":"roche-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/roche-bcg-matrix.webp?v=1776731362","url":"https:\/\/bcgmatrixtemplate.com\/products\/roche-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}